Thermo Fisher Scientific Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) decreased by 99.2% to $2.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 99.9%, from $1.81B to $2.00M. Over 2 years (FY 2023 to FY 2025), Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) shows an upward trend with a 818.3% CAGR.
An increase suggests a conservative cash management strategy or accumulation of capital for future strategic investments, while a decrease may indicate cash deployment for acquisitions or capital expenditures.
This represents liquid financial instruments held by the company that are intended to be held for more than one year or...
Commonly reported by technology firms with significant cash balances; peers often hold similar portfolios of marketable securities.
non_current_assets_short_term_investments| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.00M | $1.75B | $1.75B | $2.00B | $1.56B | $1.81B | $1.81B | $1.56B | $253.00M | $2.00M |
| QoQ Change | — | >999% | -0.1% | +14.3% | -21.9% | +16.1% | +0.1% | -13.8% | -83.8% | -99.2% |
| YoY Change | — | — | — | — | >999% | +3.5% | +3.7% | -21.8% | -83.8% | -99.9% |